168 related articles for article (PubMed ID: 21270445)
1. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
[TBL] [Abstract][Full Text] [Related]
2. SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome.
Li Y; Wang J; Yu M; Wang Y; Zhang H; Yin J; Li Z; Li T; Yan H; Li F; Wang X
Leuk Lymphoma; 2018 Oct; 59(10):2405-2413. PubMed ID: 29334836
[TBL] [Abstract][Full Text] [Related]
3. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
[TBL] [Abstract][Full Text] [Related]
4. BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.
Esmailzadeh S; Huang Y; Su MW; Zhou Y; Jiang X
Leukemia; 2015 Jun; 29(6):1402-13. PubMed ID: 25578476
[TBL] [Abstract][Full Text] [Related]
5. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.
Harro CM; Perez-Sanz J; Costich TL; Payne KK; Anadon CM; Chaurio RA; Biswas S; Mandal G; Rigolizzo KE; Sprenger KB; Mine JA; Showe LC; Yu X; Liu K; Rodriguez PC; Pinilla-Ibarz J; Sokol L; Conejo-Garcia JR
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33270606
[TBL] [Abstract][Full Text] [Related]
6. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression.
Contassot E; Kerl K; Roques S; Shane R; Gaide O; Dupuis M; Rook AH; French LE
Blood; 2008 May; 111(9):4780-7. PubMed ID: 18314443
[TBL] [Abstract][Full Text] [Related]
7. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
8. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
9. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
10. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
11. Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome.
Herrera A; Fredholm S; Cheng A; Mimitou EP; Seffens A; Bar-Natan M; Sun A; Latkowski JA; Willerslew-Olsen A; Buus TB; Gluud M; Krejsgaard T; Torres-Rusillo S; Bonefeld CM; Woetmann A; Geisler C; Geskin LJ; Ouyang Z; Smibert P; Ødum N; Koralov SB
J Invest Dermatol; 2020 Mar; 140(3):713-716. PubMed ID: 31465740
[No Abstract] [Full Text] [Related]
12. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
[TBL] [Abstract][Full Text] [Related]
13. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation.
Jones CL; Wain EM; Chu CC; Tosi I; Foster R; McKenzie RC; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2010 Apr; 130(4):1116-25. PubMed ID: 19759548
[TBL] [Abstract][Full Text] [Related]
15. Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma.
Bégué E; Jean-Louis F; Bagot M; Jauliac S; Cayuela JM; Laroche L; Parquet N; Bachelez H; Bensussan A; Courtois G; Michel L
Blood; 2012 Jul; 120(1):143-54. PubMed ID: 22627769
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
17. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
19. CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death.
Rappl G; Abken H; Muche JM; Sterry W; Tilgen W; André S; Kaltner H; Ugurel S; Gabius HJ; Reinhold U
Leukemia; 2002 May; 16(5):840-5. PubMed ID: 11986945
[TBL] [Abstract][Full Text] [Related]
20. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
